Lysophosphatidic acid as an initiator of neuropathic pain: Biosynthesis and demyelination

Clinical Lipidology

Volumn 6, Issue 2, 2011, Pages 147-158

  Ueda, Hiroshi ^a   Ueda, Mutsumi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

allodynia; autotaxin; Cav 2 l; calpain; demyelination; hypoesthesia; lysophosphatidic acid; microglia; neuropathic pain

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; CALPAIN; DIZOCILPINE; EPHRIN B1; EXOENZYME C3; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 1; LYSOPHOSPHATIDIC ACID RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE C GAMMA; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SUBSTANCE P; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

AFFERENT NERVE GROUP 1; ALLODYNIA; DEMYELINATION; DOWN REGULATION; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; HYPERALGESIA; LIPOGENESIS; MICROGLIA; MYELINATED NERVE; NERVE CELL PLASTICITY; NERVE FIBER C; NERVE SPROUTING; NEUROPATHIC PAIN; NEUROPATHOLOGY; NONHUMAN; NONMYELINATED NERVE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SPINAL CORD DORSAL HORN; SPINAL CORD INJURY; SPINAL GANGLION; SYNAPTIC TRANSMISSION; UPREGULATION;

EID: 79953819989     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.10.88     Document Type: Review

References (94)

1. Apkarian AV, Baliki MN, Geha PY: Towards a theory of chronic pain. Prog. Neurobiol. 87, 81-97 (2009).
2. Costigan M, Scholz J, Woolf CJ: Neuropathic pain: a maladaptive response of the nervous system to damage. Annu. Rev. Neurosci. 32, 1-32 (2009).
3. Saade NE, Jabbur SJ: Nociceptive behavior in animal models for peripheral neuropathy: spinal and supraspinal mechanisms. Prog. Neurobiol. 86, 22-47 (2008).
4. Woolf CJ, Salter MW: Plasticity and pain role of the dorsal horn. In: Textbook of Pain. McMahon SB, Koltzenburg M (Eds). Churchill-Livingstone, NY, USA, 91-105 (2006).
5. Woolf CJ: Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy. Life Sci. 74, 2605-2610 (2004).
6. Navarro X, Vivo M, Valero-Cabre A: Neural plasticity after peripheral nerve injury and regeneration. Prog. Neurobiol. 82, 163-201 (2007).
7. 1 receptor.
8. Dray A: Neuropathic pain: emerging treatments. Br. J. Anaesth. 101, 48-58 (2008).
9. 1-mediated demyelination.
10. Scholz J, Woolf CJ: The neuropathic pain triad: neurons, immune cells and glia. Nat. Neurosci. 10, 1361-1368 (2007).
11. Milligan ED, Watkins LR: Pathological and protective roles of glia in chronic pain. Nat. Rev. Neurosci. 10, 23-36 (2009).
12. Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H: Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat. Med. 10, 712-718 (2004). Describes the first identification of the key molecule responsible for the initiation of nerve injury-induced neuropathic pain.
13. Ma L, Matsumoto M, Xie W, Inoue M, Ueda H: Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Ki-16425, a lysophosphatidic acid 1 receptor antagonist. J. Neurochem. 109, 603-610 (2009). Describes LPA initiating neuropathic pain in the early phase after injury.
14. Campbell JN, Meyer RA: Mechanisms of neuropathic pain. Neuron 52, 77-92 (2006).
15. Matsumoto M, Inoue M, Hald A, Xie W, Ueda H: Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin. J. Pharmacol. Exp. Ther. 318, 735-740 (2006).
16. Jung BF, Herrmann D, Griggs J, Oaklander AL, Dworkin RH: Neuropathic pain associated with non-surgical treatment of breast cancer. Pain 118, 10-14 (2005).
17. Baron R: Mechanisms of disease: neuropathic pain - a clinical perspective. Nat. Clin. Pract. Neurol. 2, 95-106 (2006).
18. Devigili G, Tugnoli V, Penza P et al.: The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 131, 1912-1925 (2008).
19. Leffler AS, Hansson P: Painful traumatic peripheral partial nerve injury-sensory dysfunction profiles comparing outcomes of bedside examination and quantitative sensory testing. Eur. J. Pain 12, 397-402 (2008).
20. 2+ channel α2δ ligands: novel modulators of neurotransmission. Trends Pharmacol. Sci. 28, 75-82 (2007).
21. Mao J, Price DD, Phillips LL, Lu J, Mayer DJ: Increases in protein kinase C γ immunoreactivity in the spinal cord dorsal horn of rats with painful mononeuropathy. Neurosci. Lett. 198, 75-78 (1995).
22. Malmberg AB, Chen C, Tonegawa S, Basbaum AI: Preserved acute pain and reduced neuropathic pain in mice lacking PKCg. Science 278, 279-283 (1997).
23. Lyons R: Elusive belly pain and Guillain-Barre syndrome. J. Pediatr. Health Care 22, 310-314 (2008).
24. O'Connor AB, Schwid SR, Herrmann DN, Markman JD, Dworkin RH: Pain associated with multiple sclerosis: systematic review and proposed classification. Pain 137, 96-111 (2008).
25. Scrivani SJ, Mathews ES, Maciewicz RJ: Trigeminal neuralgia. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 100, 527-538 (2005).
26. Said G: Diabetic neuropathy - a review. Nat. Clin. Pract. Neurol. 3, 331-340 (2007).
27. van Meeteren LA, Moolenaar WH: Regulation and biological activities of the autotaxin-LPA axis. Prog. Lipid Res. 46, 145-160 (2007).
28. Mills GB, Moolenaar WH: The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 3, 582-591 (2003).
29. Park KA, Vasko MR: Lipid mediators of sensitivity in sensory neurons. Trends Pharmacol. Sci. 26, 571-577 (2005).
30. Gendaszewska-Darmach E: Lysophosphatidic acids, cyclic phosphatidic acids and autotaxin as promising targets in therapies of cancer and other diseases. Acta Biochim. Pol. 55, 227-240 (2008).
31. Noguchi K, Herr D, Mutoh T, Chun J: Lysophosphatidic acid (LPA) and its receptors. Curr. Opin. Pharmacol. 9, 15-23 (2009).
32. Jalink K, Eichholtz T, Postma FR, van Corven EJ, Moolenaar WH: Lysophosphatidic acid induces neuronal shape changes via a novel, receptor-mediated signaling pathway: similarity to thrombin action. Cell Growth Differ. 4, 247-255 (1993).
33. Rivera R, Chun J: Biological effects of lysophospholipids. Rev. Physiol. Biochem. Pharmacol. 160, 25-46 (2008).
34. Fukushima N: LPA in neural cell development. J. Cell Biochem. 92, 993-1003 (2004).
35. Kingsbury MA, Rehen SK, Ye X, Chun J: Genetics and cell biology of lysophosphatidic acid receptor-mediated signaling during cortical neurogenesis. J. Cell Biochem. 92, 1004-1012 (2004).
36. Renback K, Inoue M, Ueda H: Lysophosphatidic acid-induced, pertussis toxin-sensitive nociception through a substance P release from peripheral nerve endings in mice. Neurosci. Lett. 270, 59-61 (1999).
37. Renback K, Inoue M, Yoshida A, Nyberg F, Ueda H: Vzg-1/lysophosphatidic acid-receptor involved in peripheral pain transmission. Brain Res. Mol. Brain Res. 75, 350-354 (2000).
38. Xie W, Uchida H, Nagai J, Ueda M, Chun J, Ueda H: Calpain-mediated down-regulation of myelin-associated glycoprotein in lysophosphatidic acid-induced neuropathic pain. J. Neurochem. 113, 1002-1011 (2010).
39. 1 receptor-mediated neuropathic pain. Mol. Pain 2, 25 (2006).
40. Uchida H, Matsumoto M, Ueda H: Profiling of BoNT/C3-reversible gene expression induced by lysophosphatidic acid: EphrinB1 gene up-regulation underlying neuropathic hyperalgesia and allodynia. Neurochem. Int. 54, 215-221 (2009). Describes the profiling of LPA-induced RhoA-mediated gene expression in the dorsal root ganglion.
41. Stortelers C, Kerkhoven R, Moolenaar WH: Multiple actions of lysophosphatidic acid on fibroblasts revealed by transcriptional profiling. BMC Genomics 9, 387 (2008).
42. Rosen LB, Ginty DD, Weber MJ, Greenberg ME: Membrane depolarization and calcium influx stimulate MEK and MAP kinase via activation of Ras. Neuron 12, 1207-1221 (1994).
43. Ji RR, Baba H, Brenner GJ, Woolf CJ: Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nat. Neurosci. 2, 1114-1119 (1999).
44. Dai Y, Iwata K, Fukuoka T et al.: Phosphorylation of extracellular signal-regulated kinase in primary afferent neurons by noxious stimuli and its involvement in peripheral sensitization. J. Neurosci. 22, 7737-7745 (2002).
45. Matsumoto M, Xie W, Ma L, Ueda H: Pharmacological switch in Aβ-fiber stimulation-induced spinal transmission in mice with partial sciatic nerve injury. Mol. Pain 4, 25 (2008).
46. Matsumoto M, Inoue M, Hald A, Yamaguchi A, Ueda H: Characterization of three different sensory fibers by use of neonatal capsaicin treatment, spinal antagonism and a novel electrical stimulation-induced paw flexion test. Mol. Pain 2, 16 (2006).
47. Woolf CJ, Shortland P, Coggeshall RE: Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature 355, 75-78 (1992).
48. Woolf CJ, Shortland P, Reynolds M, Ridings J, Doubell T, Coggeshall RE: Reorganization of central terminals of myelinated primary afferents in the rat dorsal horn following peripheral axotomy. J. Comp. Neurol. 360, 121-134 (1995).
49. Bao L, Wang HF, Cai HJ et al.: Peripheral axotomy induces only very limited sprouting of coarse myelinated afferents into inner lamina II of rat spinal cord. Eur. J. Neurosci. 16, 175-185 (2002).
50. Jancso G, Santha P, Szigeti C, Dux M: Selective C-fiber deafferentation of the spinal dorsal horn prevents lesion-induced transganglionic transport of choleragenoid to the substantia gelatinosa in the rat. Neurosci. Lett. 361, 204-207 (2004).
51. Furue H, Katafuchi T, Yoshimura M: Sensory processing and functional reorganization of sensory transmission under pathological conditions in the spinal dorsal horn. Neurosci. Res. 48, 361-368 (2004).
52. 1 receptor-mediated synaptic reorganization of primary afferent fibers after nerve injury.
53. Pentland B, Donald SM: Pain in the Guillain-Barre syndrome: a clinical review. Pain 59, 159-164 (1994).
54. Osterberg A, Boivie J, Thuomas KA: Central pain in multiple sclerosis - prevalence and clinical characteristics. Eur. J. Pain 9, 531-542 (2005).
55. Fujita R, Kiguchi N, Ueda H: LPA-mediated demyelination in ex vivo culture of dorsal root. Neurochem. Int. 50, 351-355 (2007). Describes the in vitro model for demyelination involved in LPA receptor-mediated neuropathic pain.
56. v1.6 is expressed along nonmyelinated axons and it contributes to conduction. Brain Res. Mol. Brain Res. 105, 19-28 (2002).
57. Gillespie CS, Sherman DL, Fleetwood-Walker SM et al.: Peripheral demyelination and neuropathic pain behavior in periaxin-deficient mice. Neuron 26, 523-531 (2000).
58. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH: The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem. J. 291(Pt 3), 677-680 (1993).
59. Schumacher KA, Classen HG, Spath M: Platelet aggregation evoked in vitro and in vivo by phosphatidic acids and lysoderivatives: identity with substances in aged serum (DAS). Thromb. Haemost. 42, 631-640 (1979).
60. Fukushima N, Ye X, Chun J: Neurobiology of lysophosphatidic acid signaling. Neuroscientist 8, 540-550 (2002).
61. Ye X, Fukushima N, Kingsbury MA, Chun J: Lysophosphatidic acid in neural signaling. Neuroreport 13, 2169-2175 (2002).
62. Kingsbury MA, Rehen SK, Contos JJ, Higgins CM, Chun J: Non-proliferative effects of lysophosphatidic acid enhance cortical growth and folding. Nat. Neurosci. 6, 1292-1299 (2003).
63. Ishii I, Fukushima N, Ye X, Chun J: Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem, 73, 321-354 (2004).
64. Meyer zu Heringdorf D, Jakobs KH: Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim. Biophys. Acta 1768, 923-940 (2007).
65. Jessen KR, Mirsky R: Negative regulation of myelination: relevance for development, injury, and demyelinating disease. Glia 56, 1552-1565 (2008).
66. Parkinson DB, Bhaskaran A, Arthur-Farraj P et al.: c-Jun is a negative regulator of myelination. J. Cell Biol. 181, 625-637 (2008).
67. Marinissen MJ, Chiariello M, Tanos T, Bernard O, Narumiya S, Gutkind JS: The small GTP-binding protein RhoA regulates c-Jun by a ROCK-JNK signaling axis. Mol. Cell 14, 29-41 (2004).
68. Sleeper AA, Cummins TR, Dib-Hajj SD et al.: Changes in expression of two tetrodotoxin-resistant sodium channels and their currents in dorsal root ganglion neurons after sciatic nerve injury but not rhizotomy. J. Neurosci. 20, 7279-7289 (2000).
69. Dib-Hajj SD, Fjell J, Cummins TR et al.: Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain 83, 591-600 (1999).
70. Rashid MH, Inoue M, Matsumoto M, Ueda H: Switching of bradykinin-mediated nociception following partial sciatic nerve injury in mice. J. Pharmacol. Exp. Ther. 308, 1158-1164 (2004).
71. Malmberg AB, Basbaum AI: Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. Pain 76, 215-222 (1998).
72. Wieseler-Frank J, Maier SF, Watkins LR: Glial activation and pathological pain. Neurochem. Int. 45, 389-395 (2004).
73. Moalem G, Tracey DJ: Immune and inflammatory mechanisms in neuropathic pain. Brain Res. Rev. 51, 240-264 (2006).
74. Trang T, Beggs S, Salter MW: Purinoceptors in microglia and neuropathic pain. Pflugers Arch. 452, 645-652 (2006).
75. Ma L, Nagai J, Ueda H: Microglial activation mediates de novo lysophosphatidic acid production in a model of neuropathic pain. J. Neurochem. 115, 643-653 (2010).
76. Raghavendra V, Tanga F, DeLeo JA: Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J. Pharmacol. Exp. Ther. 306, 624-630 (2003).
77. 1 receptor-mediated demyelination of dorsal root fibers by sciatic nerve injury and intrathecal lysophosphatidylcholine. Mol. Pain 6, 78 (2010).
78. Inoue M, Ma L, Aoki J, Ueda H: Simultaneous stimulation of spinal NK1 and NMDA receptors produces LPC which undergoes ATX-mediated conversion to LPA, an initiator of neuropathic pain. J. Neurochem. 107, 1556-1565 (2008).
79. Aoki J: Mechanisms of lysophosphatidic acid production. Semin. Cell Dev. Biol. 15, 477-489 (2004).
80. Tokumura A, Majima E, Kariya Y et al.: Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem. 277, 39436-39442 (2002).
81. Umezu-Goto M, Kishi Y, Taira A et al.: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 158, 227-233 (2002).
82. 2 activation by bradykinin in MDCK-D1 cells. Am. J. Physiol. 272, C1380-C1387 (1997).
83. 2. Biol. Pharm. Bull. 27, 1168-1173 (2004).
84. 2 translocates to membrane fraction in human neutrophils activated by stimuli that phosphorylate mitogen-activated protein kinase. Proc. Natl Acad. Sci. USA 91, 3142-3146 (1994).
85. Smani T, Zakharov SI, Csutora P, Leno E, Trepakova ES, Bolotina VM: A novel mechanism for the store-operated calcium influx pathway. Nat. Cell Biol. 6, 113-120 (2004).
86. 2β-mediated pathway. J. Biol. Chem. 281, 34926-34935 (2006).
87. Inoue M, Ma L, Aoki J, Chun J, Ueda H: Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain. Mol. Pain 4, 6 (2008).
88. Inoue M, Xie W, Matsushita Y, Chun J, Aoki J, Ueda H: Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid. Neuroscience 152, 296-298 (2008).
89. Kotter MR, Zhao C, van Rooijen N, Franklin RJ: Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol. Dis. 18, 166-175 (2005).
90. Jeffery ND, Blakemore WF: Remyelination of mouse spinal cord axons demyelinated by local injection of lysolecithin. J. Neurocytol. 24, 775-781 (1995).
91. Ousman SS, David S: MIP-1a, MCP-1, GM-CSF, and TNF-α control the immune cell response that mediates rapid phagocytosis of myelin from the adult mouse spinal cord. J. Neurosci. 21, 4649-4656 (2001).
92. 3 receptors underlying neuropathic pain.
93. Su AI, Cooke MP, Ching KA et al.: Large-scale analysis of the human and mouse transcriptomes. Proc. Natl Acad. Sci. USA 99, 4465-4470 (2002).
94. 2 and autotaxin in nerve injury-induced neuropathic pain. J. Pharmacol. Exp. Ther. 333, 540-546 (2010).